Having trouble viewing this email? View in your browser.

The immune system is built to communicate what’s going on. Our mission is to listen.

MeMed decodes the host-immune response to generate Insights that address tough clinical dilemmas and improve lives. We are excited to announce recent news that our host-immune response technology for COVID-19 risk stratification, MeMed COVID-19 Severity, has received CE Mark.

MeMed COVID-19 Severity measures multiple proteins from a single serum sample and applies machine learning to stratify the risk of COVID-19 patients to experience severe outcomes.

Learn More!

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.